ArticleScientific reports2025
To explore the relationship between multiple glycemic markers and all-cause mortality in patients with severe atrial fibrillation based on multiple databases.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation is a common cardiac arrhythmia that significantly increases the risk of morbidity and mortality in critically ill patients. This study aimed to investigate the associations between glycemic control indicators-hemoglobin A1c (HbA1c), hemoglobin glycation index (HGI), stress hyperglycemia ratio (SHR), and glycemic variability (GV)-and clinical outcomes in AF patients admitted to intensive care unit (ICU). We conducted a retrospective analysis utilizing data from the Critical Care Medicine Information Marketplace (MIMIC)-IV database and a cohort from Binhai County People's Hospital, comprising patients with AF. Key endpoints included all-cause mortality during ICU stay and at 28-day post-ICU. Statistical analyses involved Kaplan-Meier survival curves, univariable and multivariable Cox regression models, smooth fitting curve, sensitivity analysis and weighted quantile sum (WQS) modeling. Finally, a total of 952 AF patients from MIMIC-IV database and 286 patients of Binhai People's Hospital due to AF were included for external verification. The results indicated that GV was the strongest predictor of mortality, with higher levels correlating with an increased risk of death (area under curve (AUC) = 0.620 for ICU mortality; AUC = 0.607 for 28-day post-ICU mortality). HGI and SHR also demonstrated significant associations with mortality outcomes, particularly in specific subgroups. Notably, lower HGI levels were linked to increased ICU mortality risk (log-rank P = 0.006). GV was the dominant factor in both outcomes and had a higher weight for death at 28 days after ICU (62.7% for ICU mortality vs. 47.3% for 28-day post-ICU mortality). These findings suggest that glycemic control is critical for improving outcomes in critically ill AF patients, highlighting the need for targeted interventions in managing hyperglycemia and its variability. Future studies should explore the mechanisms underlying these associations and assess the impact of glycemic management strategies on patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.